These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11488197)

  • 41. FDA finds more evidence of BSE compliance problems.
    J Am Vet Med Assoc; 2001 Aug; 219(4):427. PubMed ID: 11518162
    [No Abstract]   [Full Text] [Related]  

  • 42. Raising the bar. FDA issues final regulations on bar-code adoption.
    Becker C
    Mod Healthc; 2004 Mar; 34(9):8-9, 16. PubMed ID: 15029679
    [No Abstract]   [Full Text] [Related]  

  • 43. International Conference on Harmonisation; choice of control group and related issues in clinical trials; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2001 May; 66(93):24390-1. PubMed ID: 12356096
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The new FDA combination products programme.
    Donawa M
    Med Device Technol; 2002 Oct; 13(8):25-8. PubMed ID: 12416330
    [TBL] [Abstract][Full Text] [Related]  

  • 45. U.S. medical device reporting: who is responsible?
    Donawa M
    Med Device Technol; 2005 Apr; 16(3):27-9. PubMed ID: 15871421
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Advancing TB vaccines to Phase I clinical trials in the US: regulatory/manufacturing/licensing issues.
    Rowland SS; Mayner RL; Barker L
    Tuberculosis (Edinb); 2005; 85(1-2):39-46. PubMed ID: 15687026
    [TBL] [Abstract][Full Text] [Related]  

  • 47. When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.
    Huang SM; Temple R; Xiao S; Zhang L; Lesko LJ
    Clin Pharmacol Ther; 2009 Nov; 86(5):475-9. PubMed ID: 19844224
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A plan that establishes a framework for achieving mutual recognition of good manufacturing practices inspections.
    Horton LR; Hastings KE
    Food Drug Law J; 1998; 53(3):527-35. PubMed ID: 10346725
    [No Abstract]   [Full Text] [Related]  

  • 49. FDA set to tighten guidelines on industry dissemination of information on unapproved uses of medical products.
    Lang L
    Gastroenterology; 2008 Apr; 134(4):905. PubMed ID: 18395067
    [No Abstract]   [Full Text] [Related]  

  • 50. Schering-Plough agrees to pay FDA $500 million and bring factories into compliance.
    Kuehn BM
    J Am Vet Med Assoc; 2002 Jul; 221(2):174, 180. PubMed ID: 12118571
    [No Abstract]   [Full Text] [Related]  

  • 51. Software validation and FDA inspections.
    Young JM
    Healthc Inform; 1990 Nov; 7(11):34-5. PubMed ID: 10120734
    [No Abstract]   [Full Text] [Related]  

  • 52. Coping with the IVD directive.
    Gower G
    Med Device Technol; 2000 Oct; 11(8):28-9. PubMed ID: 11185185
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of globalization of drug manufacturing, production, and sourcing and challenges for American drug safety.
    Woo J; Wolfgang S; Batista H
    Clin Pharmacol Ther; 2008 Mar; 83(3):494-7. PubMed ID: 18253142
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A comparative method of evaluating quality of international clinical studies in China: Analysis of site visit reports of the Clinical Research Operations and Monitoring Center.
    Chang JJ; Xu J; Fan D
    Contemp Clin Trials; 2008 Sep; 29(5):654-62. PubMed ID: 18450522
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Survey says. FDA researches number of hospitals reprocessing inhouse.
    Burke E
    Mater Manag Health Care; 2002 Nov; 11(11):25-6. PubMed ID: 12491754
    [No Abstract]   [Full Text] [Related]  

  • 56. International Conference on Harmonisation; guidance on the M4 Common Technical Document--Quality: Questions and Answers/Location Issues; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Jun; 69(111):32358-9. PubMed ID: 15188781
    [TBL] [Abstract][Full Text] [Related]  

  • 57. US academia held accountable for GM products.
    Powell K
    Nat Biotechnol; 2003 Jul; 21(7):720-1. PubMed ID: 12833077
    [No Abstract]   [Full Text] [Related]  

  • 58. Vaccine industry perspective of current issues of good manufacturing practices regarding product inspections and stability testing.
    Monahan TR
    Clin Infect Dis; 2001 Dec; 33 Suppl 4():S356-61. PubMed ID: 11709773
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Corporate compliance programs for FDA-regulated companies: incentives for their development and the impact of the federal sentencing guidelines for organizations.
    Freyer DH
    Food Drug Law J; 1996; 51(2):225-42. PubMed ID: 11820200
    [No Abstract]   [Full Text] [Related]  

  • 60. US guidance on formatting 510(k)s.
    Donawa M
    Med Device Technol; 2006 Mar; 17(2):27-9. PubMed ID: 16610716
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.